Biofrontera AG (XTER:B8F) FCF Margin % : 0.00% (As of Sep. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Biofrontera AG FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Biofrontera AG's Free Cash Flow for the three months ended in Sep. 2023 was €0.00 Mil. Biofrontera AG's Revenue for the three months ended in Sep. 2023 was €7.02 Mil. Therefore, Biofrontera AG's FCF Margin % for the quarter that ended in Sep. 2023 was 0.00%.

As of today, Biofrontera AG's current FCF Yield % is -22.34%.

The historical rank and industry rank for Biofrontera AG's FCF Margin % or its related term are showing as below:

XTER:B8F' s FCF Margin % Range Over the Past 10 Years
Min: -261.37 Med: -111.77 Max: 103.55
Current: -17.03

During the past 13 years, the highest FCF Margin % of Biofrontera AG was 103.55%. The lowest was -261.37%. And the median was -111.77%.

XTER:B8F's FCF Margin % is ranked worse than
74.44% of 1029 companies
in the Drug Manufacturers industry
Industry Median: -0.47 vs XTER:B8F: -17.03

Biofrontera AG FCF Margin % Historical Data

The historical data trend for Biofrontera AG's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera AG FCF Margin % Chart

Biofrontera AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

-66.08

-111.14

-11.94

103.55

-18.94

Biofrontera AG Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Biofrontera AG's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biofrontera AG's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Biofrontera AG's FCF Margin % falls into.

Biofrontera AG FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Biofrontera AG's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-4.876	/	25.738
	=	-18.94 %

Biofrontera AG's FCF Margin for the quarter that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	0	/	7.015
	=	0.00 %

Biofrontera AG FCF Margin % Related Terms

Thank you for viewing the detailed overview of Biofrontera AG's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biofrontera AG (XTER:B8F) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera AG (XTER:B8F) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

B8F:Germany B8F:Germany B8F:Germany

Address

Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377

Website

https://www.biofrontera.com

Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.

Biofrontera AG (XTER:B8F) Headlines

No Headlines